Acoramidis for treating transthyretin amyloidosis with cardiomyopathy

the cost-comparison process, NHS England and integrated care boards have agreed to provide funding to implement this guidance 30 days after publication. 3.2 The Welsh ministers have issued directions to the NHS in Wales on implementing NICE technology appraisal guidance. When a NICE technology appraisal guidance recommends the use of a drug or treatment, or other technology, the NHS in Wales must usually provide funding and resources for it within 60 days of the first publication of the final draft guidance. 3.3 When NICE recommends a treatment 'as an option', the NHS must make sure it is available within the period set out in the paragraphs above. This means that, if a patient has transthyretin amyloidosis with cardiomyopathy and the healthcare professional responsible for their care thinks that acoramidis is the right treatment, it should be available for use, in line with NICE's recommendations.
